Glaxosmithkline Pharmaceuticals Ltd NSE  /  BSE

Pharmaceuticals, Mid Cap

17 Sep 2021 | 04:14 PM

1,538.95
-34.00 (-2.16%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 10-Mar-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 10-Mar-2020 at a price of 1311.00.

  • Valuation Rating

    Moderately overvalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately overvalued.

  • MT Tech Trend

    Trend positive since 10-Apr-2020

    The forty day Medium Term Technical Trend is positive since 10-Apr-2020. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 1338.607.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative performance versus SENSEX30 is .

Risk parameters

  • Risk Zone

    Low

    The stock has been on the low-sensitivity level since 03-Jan-2020.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -149%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 284%.

  • Beta

    37 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 37%.

  • Correlation

    0.36 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.172.87 The medium term value at risk is estimated at 172.87 or 0.11970%

    The value at risk is estimated at 172.87. The risk is therefore 0.11970%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    28.12 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    38.18 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    0.78 15.868% premium to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential: 15.868% premium.

  • Dividend Yield

    1.54% Dividend is covered by profits, but not strongly

    The twelve month estimated dividend yield represents 58.790% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 28-Feb-2020.